Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RANI THERAPEUTICS HOLDINGS, INC.

(RANI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

09/23/2021 | 04:06pm EST

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Events page in the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company focused on the oral delivery of biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com

Source: Rani Therapeutics


Primary Logo


ę GlobeNewswire 2021
All news about RANI THERAPEUTICS HOLDINGS, INC.
11/16RANI THERAPEUTICS : Reports Third Quarter 2021 Financial Results, Provides Corporate Updat..
PU
11/16RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Con..
AQ
11/15Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
GL
11/15Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
GL
11/12RANI THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/12Rani Therapeutics Appoints Lyn Baranowski to Board of Directors
AQ
11/12Rani Therapeutics Holdings, Inc. Appoints Lyn Baranowski to Board of Directors
CI
11/10Rani Therapeutics to Participate in a Fireside Chat at the Stifel 2021 Virtual Healthca..
AQ
09/29RANI THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
09/23Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
GL
More news
Analyst Recommendations on RANI THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 4,44 M - -
Net income 2021 -53,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -19,0x
Yield 2021 -
Capitalization 429 M 429 M -
Capi. / Sales 2021 96,6x
Capi. / Sales 2022 643x
Nbr of Employees 91
Free-Float 9,27%
Chart RANI THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Rani Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RANI THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 21,76 $
Average target price 28,40 $
Spread / Average Target 30,5%
EPS Revisions
Managers and Directors
Talat Imran Chief Executive Officer & Director
Svai S. Sanford Chief Financial Officer
Mir A. Imran Executive Chairman
Mir Hashim Chief Scientific Officer
Dennis Arthur Ausiello Independent Director
Sector and Competitors
1st jan.Capi. (M$)
RANI THERAPEUTICS HOLDINGS, INC.0.00%429
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298